Iatrogenic Ovarian Hyperstimulation Syndrome in Late Luteal Phase – A Rare Case Report
LifeScience-Gynaecology
DOI:
https://doi.org/10.22376/ijlpr.2023.13.6.L280-L285Keywords:
polycystic ovarian syndrome, ovarian torsion, ovulation induction, Hyperstimulation, Secondary InfertilityAbstract
Ovarian hyperstimulation syndrome is an iatrogenic medical complication unique to stimulatory infertility treatment.Characteristics of the syndrome include cystic ovarian enlargement, increased capillary permeability resulting in extravascularfluid accumulation, and intravascular volume depletion. It is a self-limiting disease in mild cases but can cause renal failure,hydrothorax, and respiratory distress that can cause mortality in severe cases. In this case, we aimed to report moderateovarian hyperstimulation (grade 3) syndrome, ultimately resulting in ovarian torsion and salphingo oophorectomy. Casepresentation-A 29-year-old female known case of polycystic ovarian syndrome underwent ovulation induction 22 days later. Shepresented to our hospital with severe abdominal pain, abdominal distension, and vomiting. She was admitted and diagnosed withGrade 3 Ovarian hyperstimulation syndrome medical management, given the patient got better symptomatically. 10 days later,she presented in casualty with abdominal pain and was diagnosed with right ovarian torsion and right salphingo oophorectomydone. Conclusion: We should rule out risk factors for ovarian Hyperstimulation syndrome before treating any infertility patient.Patients with ovarian hyperstimulation syndrome must be identified early and referred urgently to a tertiary care hospital.Ovarian hyperstimulation syndrome can result in serious morbidity and mortality if left untreated
References
Gul T, Ugurel V. A Case of Ovarian Hyperstimulation Syndrome in Patient With Polycystic Ovarian Syndrome. T Gul 2015. Available from: https://cms.galenos.com.tr.
Palshetkar N, Roongta N. Protocols for ovulation induction. Mumbai Obstetric and Gynecological Society; 2011.
Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006;12(4):333-40. doi: 10.1093/humupd/dml001, PMID 16567347.
Practice Committee of the American Society for Reproductive Medicine. Use of exogenous gonadotropins in anovulatory women: a technical bulletin. Fertil Steril. 2008;90(5);Suppl:S7-12. doi: 10.1016/j.fertnstert.2008.08.003, PMID 19007651.
Kumar P, Sait SF, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci. 2011;4(2):70-5. doi: 10.4103/0974-1208.86080, PMID 22065820.
Hugues j .ovarian stimulation for assisted reproductive technologies. Current practices and controversies in assisted reproduction. Geneva, Switzerland: WHO; 2001. p. 102-26.
Vayena E, Rowe PJ, Griffin PD. Current practices and controversies in assisted reproduction: report of a meeting on medical, ethical, and social aspects of assisted reproduction, held at WHO, Headquarters, Geneva, Switzerland. World Health Organization; 2002.
Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. 2000;73(5):883-96. doi: 10.1016/S0015-0282(00)00491-X, PMID 10785212.
Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997;3(3):255-66. doi: 10.1093/humupd/3.3.255, PMID 9322101.
Delbaere A, Bergmann PJM, Gervy-Decoster C, Camus M, de Maertelaer V, Englert Y. Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome. Hum Reprod. 1997;12(2):236-40. doi: 10.1093/humrep/12.2.236, PMID 9070702.
Aubuchon M et al. Infertility and assisted reproductive technology. In: Berek DL, Timothy C, Barlie G, editors. Berek &Novak's gynecology. 15thed. Philadelphia: Wolters kluwer; 2012.
Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an updated review. Obstet Gynecol Surv. 1989;44(6):430-40. doi: 10.1097/00006254-198906000-00004, PMID 2660037.
Royal College of Obstetrics and Gynaecology. Managing ovarian hyperstimulation syndrome, Green-top Guideline(5, Feb); 2016.
Todros T, Carmazzi CM, Bontempo S, Gaglioti P, Donvito V, Massobrio M. Spontaneous ovarian hyperstimulation syndrome and deep vein thrombosis in pregnancy: a case report. Hum Reprod. 1999;14(9):2245-8. doi: 10.1093/humrep/14.9.2245, PMID 10469688.
Delvigne A. Symposium: update on prediction and management of OHSS. Epidemiology of OHSS. Reprod Biomed Online. 2009 Jan 1;19(1):8-13. doi: 10.1016/s1472-6483(10)60040-5, PMID 19573285.
Avecillas JF, Falcone T, Arroliga AC. Ovarian hyperstimulation syndrome. Crit Care Clin. 2004;20(4):679-95. doi: 10.1016/j.ccc.2004.05.003, PMID 15388196.
Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: A European series and a proposal for prevention. Fertil Steril. 1990;53(3):502-9. doi: 10.1016/s0015-0282(16)53348-2, PMID 2106456.
Al Wattar BH, Fisher M, Bevington L, Talaulikar V, Davies M, Conway G, et al. Clinical practice guidelines on the diagnosis and management of polycystic ovary syndrome: a systematic review and quality assessment study. J Clin Endocrinol Metab. 2021 Jul 13;106(8):2436-46. doi: 10.1210/clinem/dgab232, PMID 33839790.
Aubuchon M, Burney RO, Schust DJ, Yao MW. Infertility and assisted reproductive technology. Berek & Novak's gynecology. 15th ed. Lippincott Williams & Wilkins, a Wolters Kluwer business; 2012. p. 1139.8. Abramov Y, Elchalal U, Schenker JG. Severe OHSS: an 'epidemic' of severe OHSS: a price we must pay? Hum Reprod. 1999;14(9):2181-3. doi: 10.1093/humrep/14.9.2181, PMID 10469676.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr. Nithya .R, Dr.ch. Yamini Uma Deepthi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
